

A&I

ANÄSTHESIOLOGIE & INTENSIVMEDIZIN

Offizielles Organ: Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI)
Berufsverband Deutscher Anästhesisten e.V. (BDA)
Deutsche Akademie für Anästhesiologische Fortbildung e.V. (DAAF)
Organ: Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e.V. (DIVI)



Tuberous sclerosis complex

Vein of Galen malformation

orphan**a**nesthesia

a project of the German Society
of Anaesthesiology and Intensive Care Medicine

SUPPLEMENT NR. 15 | 2022

OrphanAnesthesia –

ein krankheitsübergreifendes Projekt des Wissenschaftlichen Arbeitskreises Kinderanästhesie der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin e.V.

Ziel des Projektes ist die Veröffentlichung von Handlungsempfehlungen zur anästhesiologischen Betreuung von Patienten mit seltenen Erkrankungen. Damit will Orphan Anesthesia einen wichtigen Beitrag zur Erhöhung der Patientensicherheit leisten.

Patienten mit seltenen Erkrankungen benötigen für verschiedene diagnostische oder therapeutische Prozeduren eine anästhesiologische Betreuung, die mit einem erhöhten Risiko für anästhesieassoziierte Komplikationen einhergehen. Weil diese Erkrankungen selten auftreten, können Anästhesisten damit keine Erfahrungen gesammelt haben, so dass für die Planung der Narkose die Einholung weiterer Information unerlässlich ist. Durch vorhandene spezifische Informationen kann die Inzidenz von mit der Narkose assoziierten Komplikationen gesenkt werden. Zur Verfügung stehendes Wissen schafft Sicherheit im Prozess der Patientenversorgung.

Die Handlungsempfehlungen von OrphanAnesthesia sind standardisiert und durchlaufen nach ihrer Erstellung einen Peer-Review-Prozess, an dem ein Anästhesist sowie ein weiterer Krankheitsexperte (z.B. Pädiater oder Neurologe) beteiligt sind. Das Projekt ist international ausgerichtet, so dass die Handlungsempfehlungen grundsätzlich in englischer Sprache veröffentlicht werden.

Ab Heft 5/2014 werden im monatlichen Rhythmus je zwei Handlungsempfehlungen als Supplement der A&I unter www.ai-online.info veröffentlicht. Als Bestandteil der A&I sind die Handlungsempfehlungen damit auch zitierfähig. Sonderdrucke können gegen Entgelt bestellt werden.

OrphanAnesthesia –

a project of the Scientific Working Group of Paediatric Anaesthesia of the German Society of Anaesthesiology and Intensive Care Medicine

The target of OrphanAnesthesia is the publication of anaesthesia recommendations for patients suffering from rare diseases in order to improve patients' safety. When it comes to the management of patients with rare diseases, there are only sparse evidence-based facts and even far less knowledge in the anaesthetic outcome. OrphanAnesthesia would like to merge this knowledge based on scientific publications and proven experience of specialists making it available for physicians worldwide free of charge.

All OrphanAnesthesia recommendations are standardized and need to pass a peer review process. They are being reviewed by at least one anaesthesiologist and another disease expert (e.g. paediatrician or neurologist) involved in the treatment of this group of patients.

The project OrphanAnesthesia is internationally oriented. Thus all recommendations will be published in English.

Starting with issue 5/2014, we'll publish the OrphanAnesthesia recommendations as a monthly supplement of A&I (Anästhesiologie & Intensivmedizin). Thus they can be accessed and downloaded via www.ai-online.info. As being part of the journal, the recommendations will be quotable. Reprints can be ordered for payment.

Bisher in A&I publizierte Handlungsempfehlungen finden Sie unter:

www.ai-online.info/Orphsuppl
www.orphananesthesia.eu

Find a survey of the recommendations published until now on:

www.ai-online.info/Orphsuppl
www.orphananesthesia.eu



Deutsche Gesellschaft für Anästhesiologie & Intensivmedizin

www.dgai.de



ANÄSTHESIOLOGIE & INTENSIVMEDIZIN

www.ai-online.info

Projektleitung

Prof. Dr. Tino Münster, MHBA

Chefarzt
Klinik für Anästhesie und
operative Intensivmedizin
Krankenhaus Barmherzige
Brüder Regensburg
Prüfeninger Straße 86
93049 Regensburg,
Deutschland

Tel.: 0941 369-2350

E-Mail: Tino.Muenster@barmherzige-regensburg.de

orphan^aesthesia

Anaesthesia recommendations for Tuberous sclerosis complex

Disease name: Tuberous sclerosis complex

ICD 10: Q85.1

Synonyms: Tuberous sclerosis, Bourneville disease, Epiloia

Disease summary: Tuberous sclerosis complex (TSC) is an uncommon, neurocutaneous multisystem genetic disorder. It was classically described as presenting in childhood with a pathognomonic triad (Vogt triad) of seizures (absent in one-quarter of individuals), intellectual disability (up to half have normal intelligence) and sebaceous adenoma (only present in about three-quarters of the patients) [1]. The full triad is only seen in a minority of patients (~ 30 %). Therefore, diagnostic criteria have been developed to aid the diagnosis of tuberous sclerosis.

There are 2 genetic loci: TSC1, found on chromosome 9q34; and TSC2, found on chromosome 16p13 [2,3,4] coding for the proteins hamartin and tuberin, respectively. These proteins act as tumour growth suppressors, regulating cell proliferation and differentiation. In TSC patients, TSC1 or TSC2 mutations give rise to hyperactivation of the mTOR pathway, inducing several abnormalities in numerous cell biochemical processes such as cell cycle regulation and control at transcriptional, translational, and metabolic levels [5]. More recently, mTOR inhibitor drugs, such as everolimus, have been licensed for use in the treatment of specific clinical manifestations of TSC in certain countries, e.g., subependymal giant cell astrocytomas, renal angiomyolipomas, therapy of refractory epilepsy [6] and in patients with cardiac or pulmonary involvement. Everolimus can take over the function of the proteins hamartin and tuberin, which are missing due to the genetic defect. Approximately one-third of the patients inherit mutations via the autosomal dominant route with the remaining two-thirds of patients born with new sporadic mutations. The TSC2 gene is more common in both the familial and sporadic forms of the condition. The incidence is approximately 1 in 5,000 – 10,000 live births [7].

The condition is characterised by cellular hyperplasia, tissue dysplasia, and multiple organ hamartomas (benign tumours). TSC shows wide phenotypical variability with patients harbouring the TSC2 gene exhibiting the more severe clinical manifestations. The benign tumours seen in TSC can occur in almost all organ systems, e.g., on the skin, brain, kidneys, heart, lungs, liver, spleen, pancreas, gastrointestinal tract, gingivae and the retinas. Clinical symptoms may include epilepsy, which can be refractory, developmental delay, behavioural problems, and autism. Three types of brain tumour are commonly associated with the condition: giant cell astrocytoma, cortical tubers (after which the disease is named) and subependymal nodules. The growths on the kidneys can be angiomyolipomas (AMLs) or renal cysts. Renal AMLs can produce pain and haemorrhage in adulthood, whereas the cysts are more likely to cause damage to the renal parenchyma causing hypertension and chronic kidney disease which is exhibited in < 5 % of patients overall [8,9]. Cardiac rhabdomyomas are single or multiple and can be seen antenatally. If symptomatic, they present in the

► **Citation:** Carter L, Ioannou I: Tuberous sclerosis complex. *Anästh Intensivmed* 2022;63:S378–S390.
DOI: 10.19224/ai2022.S378

neonatal period, but this is rare. They tend to regress in childhood without the need for intervention [2,8]. Lymphangiomyomatosis (LAM) of the lungs occurs in 40 % of women with TSC and appears to be hormonally sensitive. It can cause recurrent pneumothoraces [10] and in some cases leads to progressive, irreversible cystic cavitations within the lungs. For certain patients, this can ultimately lead to death without lung transplantation.

The main anaesthetic concerns in the treatment of patients with TSC are related to cardio-respiratory complications secondary to progressive damage to the lung parenchyma in adults and the potential for arrhythmias, outflow tract obstruction and venous thromboembolic events in children. Consideration must also be given to anaesthetic drug choices in view of possible renal impairment and medications that the patients may have been prescribed to take long term. Oral lesions on the tongue, palate and less commonly the pharynx and larynx may interfere with anaesthetic airway management [11,12]. In addition, practical difficulties may arise when anaesthetising patients with developmental delay and challenging behaviour. Despite ongoing research into TSC, certain aspects related to its diagnosis and treatment remain unexplained, therefore, the anaesthetist is presented with challenges when planning the perioperative management of these patients.

Medicine is in progress



Perhaps new knowledge

Every patient is unique

Perhaps the diagnosis is wrong



Find more information on the disease, its centres of reference and patient organisations on Orphanet: www.orpha.net

Typical surgery

Common surgeries seen in patients with TSC include: acute decompressive neurosurgical procedures [13,14], resective neurosurgery and vagal nerve stimulator implantation for epilepsy. In the case of renal AMLs, selective arterial embolisation [15,16] is often the preferred treatment method to minimise bleeding, whereas previously partial nephrectomy was commonly performed in preference to total nephrectomy. Sometimes a combined radiological and surgical approach may be employed to treat these lesions. Thoracic procedures such as pleurodesis and video-assisted thoracic surgery (VATS) [17,18] are seen more commonly than lung transplantation [13,19]. In certain cases, patients may require resection of jaw and oral lesions.

Anaesthesia may also be necessary for diagnostic and minimally invasive procedures such as MRI scans in children who, in addition to TSC, may exhibit signs of developmental delay. Other surgical procedures requiring anaesthesia include resection of jaw and oral lesions and surgery to the skin or laser treatment for facial AMLs.

Type of anaesthesia

There is no definite recommendation for general or regional anaesthesia in patients with tuberous sclerosis complex [20] and both gaseous and intravenous induction of anaesthesia are considered to be safe. The spinal cord and peripheral nerves are very rarely known to be involved in the condition and, therefore, regional anaesthesia may be a viable anaesthetic option [21]. No specific anaesthetic agents or techniques are absolutely contraindicated in patients with TSC [20].

When considering any paediatric anaesthetic, it is often found that the presence of parents and carers is very helpful in reducing a child's anxiety prior to and during induction. If additional anxiolysis is required, oral or buccal pre-medications such as midazolam can play an important role in the preoperative period in children with TSC. These children often have behavioural difficulties and developmental delay, so may be anxious and uncooperative when presenting for anaesthesia.

Necessary additional preoperative testing (beside standard care)

Tuberous sclerosis complex is a multi-system disorder which is associated with significant neurological, cardio-respiratory and renal dysfunction in the patient population. These pathologies must be fully investigated preoperatively.

1. Upper airway lesions are present in 11 % of patients with TSC [21,22], and may be evaluated with imaging such as ultrasound or CT scan and, where possible, awake nasendoscopy.
2. If pulmonary involvement is suspected, pulmonary function testing and arterial blood gas analysis should be performed. Chest X-rays may miss the characteristic cysts found in LAM. If the patient is female and of child-bearing age, baseline pulmonary function testing, 6-minute walk test, and high-resolution chest computed tomography (HRCT), along with serial spirometry, are indicated in addition to the evaluation of pulmonary structural and functional abnormalities related to LAM [14,23,24]. These tests will also aid decision-making regarding the need for postoperative ventilation and intensive care admission.

3. All patients should have an electrocardiogram to rule out dysrhythmias, conduction defects or pre-excitation [20]. Echocardiography and a chest X-ray should be performed in patients who are thought to have cardiac involvement caused by cardiac rhabdomyomas. This is primarily the paediatric population.
4. Renal function should be assessed by measuring serum creatinine and/or cystatin C and by taking the patient's blood pressure. A renal ultrasound, CT or MRI should take place to detect complications of lesions such as haemorrhage, rupture or malignant transformation [7].
5. A CT or MRI of the brain should be performed to look for any signs of hydrocephalus or raised intracranial pressure caused by subependymal giant-cell astrocytomas (SEGAs) which are observed in 5–15 % of patients with TSC [19].
6. For those TS patients with epilepsy, preoperative blood tests should be taken to measure and evaluate the platelet count. Platelet aggregation studies should also be considered to look for any abnormalities of platelet function.

Particular preparation for airway management

Airway management can be complicated in patients with TSC if oral manifestations of the disease are present. These have been described in 11 % of cases [11] and can include: dental enamel pitting (48 %–100 %), gingival fibromas (50 %), bifid uvula, cleft lip and palate, high-arched palate, macroglossia, thickening of the alveolar bone and pseudocystic lesions of the mandible [39,40]. Lesions on the pharynx and larynx occur less commonly, however. Significant airway obstruction can be caused by these lesions and they also have the potential to bleed if traumatised.

Diligent assessment of the airway should be performed preoperatively and any airway imaging reviewed. An opinion from an ear, nose and throat surgeon should be sought to assess the extent of any airway lesions and awake nasendoscopy performed preoperatively if possible.

The difficult airway trolley should be available for the induction of anaesthesia. If the patient needs intubation an alternative to direct laryngoscopy should be considered. Video laryngoscopy or an AirTraq® optical laryngoscope could be useful. The preferred approach for patients with significant airway lesions is awake fibre-optic intubation, although this technique can be performed asleep in children or in patients with developmental delay [20].

Particular preparation for transfusion or administration of blood products

TSC patients with renal angiomyolipomas (AMLs) are at increased risk of requiring blood products perioperatively due to the likelihood of haemorrhage from these lesions [42]. They may rupture and cause large-volume retroperitoneal haemorrhage especially in cases of rare giant renal AMLs. Renal AMLs are hormone-sensitive and therefore tend to grow during pregnancy, thus increasing the risk of rupture and subsequent haemorrhage during pregnancy and delivery [36]. In addition, TSC patients with significant renal impairment may be anaemic preoperatively.

There is evidence from a small study that paediatric patients with TSC might exhibit platelet function abnormalities. Platelet aggregation studies should be considered in these patients having surgery with anticipated blood loss [32].

Sodium Valproate can decrease platelet count and function, as well as affecting the coagulation cascade. Furthermore, when patients are taking multiple AEDs, there is an impact on the ability of the liver to synthesise coagulation factors. Studies performed in children undergoing epilepsy surgery demonstrated abnormalities in platelet aggregation and coagulation in up to 25 % of the patients, many of these children had an underlying diagnosis of TS [43].

Particular preparation for anticoagulation

There is no evidence to support any particular method of anticoagulation in patients with TSC, but there is an increased risk of thrombus formation in neonatal patients with cardiac rhabdomyomas. This is due to the turbulent flow created around these lesions [26]. A rare case of pulmonary embolism in a neonate secondary to cardiac rhabdomyomas has been reported [44].

Particular precautions for positioning, transportation and mobilisation

Careful attention should be given perioperatively to pressure areas particularly in view of the many dermatological manifestations of TSC. Facial angiofibromas are present in 75 %–80 % of patients with TSC [19], therefore care should be taken when securing airway devices.

Interactions of chronic disease and anaesthesia medications

One of the main characteristics in patients with TSC is epilepsy, which can be refractory to treatment and very disabling. 90 % of these patients suffer from seizures that require more than one type of antiepileptic drug (AED) to achieve adequate symptomatic control. Notable pharmacokinetic and pharmacodynamic interactions exist between AEDs and common anaesthetic drugs [25], the induction and inhibition of the cytochrome P450 isoenzymes in hepatic metabolism being the most significant interaction [25,28]. This alteration in cytochrome P450 activity will alter the pharmacokinetics of many anaesthetic drugs provided that their metabolism takes place in the liver. Some first-generation AEDs, e.g., carbamazepine, phenobarbital and phenytoin, have potent enzyme-inducing properties, resulting in decreased plasma concentrations of many common anaesthetic drugs. Thus the anaesthetic requirements of these drugs will be greater. Examples of such drugs are propofol, thiopentone, midazolam, non-depolarising muscle relaxants such as rocuronium and vecuronium and opioids. Topiramate and felbamate are newer AEDs with mixed inducer and inhibitor properties [25,28] and notably cause relative resistance and higher requirements for opioids and non-depolarising neuromuscular blockers [19]. However, in comparison to the first-generation AEDs, they appear to have a lesser effect on liver enzyme activity. Sodium valproate is an inhibitor of the hepatic microsomal enzyme system, thus leading to a reduction in the required dose of anaesthetic drugs. It is important to note the interaction between sodium valproate and the carbapenem group of antibiotics. Carbapenems significantly decrease the plasma concentration of sodium valproate, exposing the patient to an increased risk of uncontrolled seizures. For this reason, the use of carbapenem antibiotics in patients taking sodium valproate should be avoided where possible. Whenever the combination is unavoidable, then either increasing the dose of sodium valproate or the addition of a second AED should be considered [46].

In recent years, the mTOR inhibitor everolimus has been approved in some countries for the treatment of certain clinical manifestations of TSC. This is an immunosuppressant drug which is taken orally and has multiple adverse side effects such as: non-infectious pneumonitis, stomatitis, infections, thrombocytopenia, rash and multiple metabolic abnormalities [47,48]. They are metabolised by CYP3A4, with enzyme inducers and inhibitors affecting the level of resultant immunosuppression [48]. CYP3A4 is a member of the cytochrome-P450 family of oxidising enzymes which is instrumental in drug metabolism. Anaesthetic volatile agents are enzyme inducers and etomidate is an enzyme inhibitor. The use of these drugs during the perioperative period may adversely affect the patient taking everolimus.

For the small proportion of TSC patients with significant renal failure, the recommendations regarding the use of anaesthetic agents and analgesics are comparable to those of patients with chronic kidney disease stages 3b–5. In case of patients with TSC, the administration of desmopressin prior to surgery could decrease the seizure threshold and interact with lamotrigine and carbamazepine [29].

Anaesthetic procedure

Most induction agents are considered safe to be used in patients with TSC, however, ketamine should be avoided as there is evidence suggesting that it lowers the seizure threshold in TSC patients and increases intracranial pressure [26,27]. Hypnotic agents such as propofol should be used with extreme caution in patients with any significant cardiac pathology and arrhythmogenic drugs should also be avoided in such cases. In neonates with cardiac failure, hypnotic agents may not be appropriate for induction.

Either a gaseous or an intravenous induction of anaesthesia is considered to be safe in most patients with TSC. Volatile agents and hypnotic agents are broadly considered to be anti-convulsant in their effects as is nitrous oxide, so these drugs are all useful in patients who are epileptic. Sevoflurane and enflurane have been rarely reported to have proconvulsant activity at low inspired concentrations [25,28]. However, higher inspired concentrations of enflurane, e.g., above MAC 2, have been associated with seizure activity [29]. Similarly, sevoflurane is considered to be safe if inspired concentrations achieving MAC 1.5 or greater are avoided. When performing an inhalation induction with sevoflurane, an inspired concentration of approximately 4 % should not be exceeded to avoid the possibility of triggering seizures [31]. A slow inhalation induction of anaesthesia in TSC patients could therefore be a safe option or, if possible, an intravenous induction would be preferable [29]. Isoflurane and halothane have primarily anticonvulsant properties. Nitrous oxide has been shown to suppress epileptiform activity [30], but should be avoided in patients with pulmonary cysts due to the risk of expansion-related rupture [41]. It is essential to maintain normocapnia, normovolemia and normothermia in patients with TSC to avoid triggering seizures during surgery. TIVA has been used safely in patients with TSC [45]. Maintenance of anaesthesia can be achieved by using a volatile agent or TIVA.

Anticholinergics such as atropine or scopolamine can produce a central cholinergic blockade (or central anticholinergic syndrome). This manifests as agitation with seizures, hallucinations, and restlessness or stupor, coma, and apnoea. The most effective treatment for this is physostigmine. Glycopyrrolate does not cross the blood–brain barrier, for which reason it does not produce these effects [25].

Non-depolarising neuromuscular blocking agents and succinylcholine have been used safely in patients with TSC [19] although care must be taken regarding drug interactions with certain AEDs. There may be a relative resistance and higher dosing requirement for non-

depolarising neuromuscular blocking agents. Atracurium and cisatracurium could be considered the ideal neuromuscular blocking agents due to their metabolism being independent of the liver and kidneys. There may be a prolonged action of muscle relaxants in TSC patients with renal failure.

There is no specific pain management method for patients with TSC although fentanyl, alfentanil, sufentanil, and morphine have been reported to cause generalised seizures in patients after administration of low-to-moderate doses, so should be used with caution [32,33]. Doses of opioids should be adjusted for TSC patients with renal disease as accumulation may also occur leading to oversedation and respiratory depression. Nonsteroidal anti-inflammatory drugs are contraindicated in patients with renal pathology.

Local anaesthetics can be used safely at specific, therapeutic, doses. At higher doses, they can cause neurotoxicity which has the potential to give rise to generalised seizures. The rate of systemic absorption of local anaesthetics depends on the administration site as well as the toxic dose so this must also be considered. The rate of absorption is greatest when a local anaesthetic is injected intra-arterially, then intravenously, tracheally, intercostally, paracervically, epidurally, into brachial plexus, into the sciatic plexus and finally subcutaneously. Alterations in metabolism and excretion of the amino amide local anaesthetics (lidocaine, bupivacaine, mepivacaine, and ropivacaine) may be noted in patients with TS affecting the kidneys. Additionally, certain antiepileptic drugs may alter the enzymatic activity of the liver. Amino amide local anaesthetics are hepatically metabolised and renally excreted. There can therefore be an increase in their plasma concentrations and consequently their systemic toxicity. Neuraxial techniques can be employed, providing advance imaging of the brain and spinal cord has been performed. Regional anaesthesia can be performed safely.

Glycopyrrolate and neostigmine can be used safely for the reversal of neuromuscular blockade at the end of surgery. The literature advises general caution when using sugammadex in cases of patients with renal failure.

Certain other drugs used during the perioperative period should be considered specifically in the case of providing anaesthesia for a patient with TSC. A high dose of tranexamic acid can potentially lower the seizure threshold. The most commonly used dose in cardiac surgery is 10mg/kg intravenous (iv) bolus, followed by an infusion of 1mg/kg/hr. Higher doses do not offer a greater haemostatic effect, yet a 25 % reduction in the total dose administered reduces the risk of seizures significantly [35].

Certain classes of antibiotics must also be used with caution. Beta-lactam antibiotics can trigger seizure activity when their beta-lactam ring acts as a competitive antagonist of the GABA receptor. Cephalosporins have been associated with a lower risk of seizures than penicillins, but seizures have been described in response to toxic concentrations. Particular attention should be paid to carbapenems, specifically imipenem, whose incidence of seizures varies from 3 to 33 %. In contrast, the seizure rate associated with meropenem is less than 1 % [37].

Flumazenil should be used with caution due to its competitive antagonism at the benzodiazepine binding site of the GABA/benzodiazepine receptor complex. It can trigger seizures in patients on chronic benzodiazepine treatment, or if benzodiazepines have been part of the anaesthetic premedication.

Particular or additional monitoring

For patients who are displaying more severe manifestations of the disease (e.g., significant hypertension, cardiac disease or renal failure) and undergoing major procedures, invasive monitoring is indicated, i.e. arterial line and central venous catheter placement. A urinary catheter should also be inserted in such cases. Central temperature monitoring should be mandatory in all surgical interventions lasting more than 30 minutes in order to avoid hyper-/hypothermia and thus an increased risk of triggering perioperative seizures. In addition, a method of perioperative electrolyte monitoring should be available to avoid physiological situations which may alter the seizure threshold of the patient with TSC, e.g., hypoglycaemia, hyponatraemia, hypomagnesaemia and hypocalcaemia.

Monitoring the depth of anaesthesia is very useful in TSC patients as it may provide information whether sub-clinical seizure activity can be detected. The bispectral index (BIS) is commonly used for monitoring the intraoperative depth of anaesthesia. The detection of seizure activity in the same instance would also need the additional computation of the spectral density matrix (SDM). The SDM is a coloured graph representing the amplitude and frequency of brain waves over time, and whose range varies from blue (minimum amplitude) to red (maximum amplitude). The anaesthetist could then identify a seizure by observing a range of low frequencies and high amplitudes on the monitor [34].

Neuromuscular blockade should be measured using a peripheral nerve stimulator because of the unpredictable nature of neuromuscular blocking drugs in TSC patients who are on AEDs or display renal failure.

Possible complications

General complications which may occur during the perioperative period in patients with TSC include arrhythmias, thromboembolic events, hypertension, increased bleeding risk and complications related to surgical positioning.

Obstruction on extubation can occur in TSC patients who have oropharyngeal lesions.

Neonatal patients are at risk of cardiac arrhythmias and thromboembolic events secondary to cardiac rhabdomyomas. These can be exacerbated by certain anaesthetic agents and dehydration.

For patients taking certain anti-epileptic drugs, there is a relative resistance to non-depolarising neuromuscular blocking drugs, for which reason higher doses are required. These drugs may also be prolonged in their action in patients with renal failure. Epileptic patients will be at increased risk of seizures if they are in a state of hyper- or hypocapnia [26]. Normocapnia should be maintained.

There will be potential for respiratory depression and increased sedation if opioids, e.g., morphine are administered to patients who have renal failure. Short-acting opioids and regional techniques would be more advantageous in such cases.

Postoperative care

A short observation period postoperatively is often all that is required following minor procedures. Many can be discharged home the same day. Others are safely discharged to normal surgical wards following inpatient surgery.

In cases of significant organ failure or if the patient requires major surgery, postoperative admission to a critical care setting should be considered [21]. Arterial blood-gas sampling should be conducted postoperatively to assess acid-base balance in TSC patients with respiratory involvement and significant renal failure. This can help to avoid postoperative seizures.

Narcosis is a complication in patients with significant renal failure due to their altered drug metabolism and excretion. Postoperative analgesia should follow a multimodal approach including the use of regional anaesthetic techniques and local anaesthetic to infiltrate wounds. This will help decrease opioid requirements. NSAIDs should be avoided in these patients.

Disease-related acute problems and effect on anaesthesia and recovery

The three main complications that must be considered during the post-operative period in TSC patients are the development of seizures, severe hypertension and bradyarrhythmias. These must be recognised quickly and treated accordingly with anti-epileptic medications, vasodilator drugs and appropriate antiarrhythmics.

Ambulatory anaesthesia

Ambulatory anaesthesia is entirely appropriate in several surgeries of patients with TSC, particularly in common procedures such as resection of cutaneous lesions.

Obstetrical anaesthesia

Anaesthetists may need to provide analgesia during labour and delivery and anaesthesia and postoperative pain relief if caesarean section is performed [49]. Epilepsy may be triggered by pain, anxiety and excitement, which are all frequent during delivery. For those with epilepsy, epidural analgesia can be beneficial, since hypocarbia induced by maternal hyperventilation during painful uterine contractions lowers the seizure threshold and therefore should be avoided [50]. Spinal lesions are rare, but cerebral lesions are more common. Pregnant women with TSC should have an MRI of their brain and spine early on in pregnancy. The result of these scans along with neurosurgical consultation will guide the decision to proceed with epidural or spinal anaesthesia [49]. Both have been used safely in TSC patients without evidence of raised intracranial pressure or any spinal lesions.

General anaesthesia can be performed for caesarean section in cases where a neuraxial technique is contraindicated.

It is important to note that renal AMLs are hormone-sensitive and have a tendency to grow during pregnancy. This may lead to an increased risk of rupture during pregnancy and delivery and therefore an increased risk of associated maternal haemorrhage [36].

References

1. Umeoka S, Koyama T, Miki Y, Akai M, Tsutsui K, Togashi K. Pictorial review of tuberous sclerosis in various organs. *Radiographics* 2008;28:e32
2. Hyman MH, Whittemore VH. National Institutes of Health consensus conference: tuberous sclerosis complex. *Arch Neurol* 2000;57:662–665
3. European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. *Cell* 1993;75:1305–1315
4. van Slechtenhorst M, de Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. *Science* 1997;277:805–808
5. Palavra F, Robalo C, Reis F. Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex. *Oxid Med Cell Longev* 2017: 9820181. DOI: 10.1155/2017/9820181
6. Lechuga L, Franz DN. Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures. *Expert Rev Neurother* 2019;19:913–925
7. Curatolo P, Bombardieri R, Jozwiak. Tuberous sclerosis. *Lancet* 2008;372:657–668
8. Gomez M, Sampson J, Whittemore V (eds.). *The tuberous sclerosis complex*. Oxford: Oxford University Press 1999
9. Kingswood JC, Bissler JJ, Budde K, Hulbert J, Guay-Woodford L, Sampson JR, et al. Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study. *Nephron* 2016;134:51–58
10. Gosein MA, Ameeral A, Konduru SK, Dola VN. Tuberous sclerosis presenting with spontaneous pneumothorax secondary to lymphangioleiomyomatosis; previously mistaken for asthma. *BMJ Case Rep* 2013;31:bcr2013009969
11. Gomez MR ed *Tuberous Sclerosis*, 2nd ed. New York: Raven Press 1988
12. Lee JJ, Imrie M, Taylor V. Anaesthesia and tuberous sclerosis. *Br J Anaesth* 1994;73: 421–425
13. Franz DN, Bissler JJ, McCormack FX. Tuberous sclerosis complex: neurological, renal and pulmonary manifestations. *Neuropediatrics* 2010;10:199–208
14. Hallett L, Foster T, Liu Z, Blieden M, Valentim J. Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic review. *Curr Med Res Opin* 2011;27:1571–1583
15. Hongyo H, Higashihara H, Osuga K, Kashiwagi E, Kosai S, Nagai K, et al. Efficacy of prophylactic selective arterial embolization for renal angiomyolipomas: identifying predictors of 50% volume reduction. *CVIR Endovasc* 2020;3:84
16. Sun P, Liu J, Charles H, Hulbert J, Bissler J. Outcomes of angioembolization and nephrectomy for renal angiomyolipoma associated with tuberous sclerosis complex: a real-world US national study. *Curr Med Res Opin* 2017;33:821–827
17. Gupta N, Henske EP. Pulmonary manifestations in tuberous sclerosis complex. *Am J Med Genet C Semin Med Genet* 2018;178:326–337
18. Tsai CF, Hsiao CH, Lee JM, Chen KC, Shieh MJ, Lai HS, et al. Video-assisted thoracoscopic surgery for recurrent pneumothorax in pulmonary lymphangioleiomyomatosis with tuberous sclerosis complex. *J Cardiothorac Surg* 2013;8:101
19. Rabito MJ, Kaye AD. Tuberous Sclerosis Complex: Perioperative Considerations. *Ochsner Journal* 2014;14:229–239
20. Fleisher LA. *Anesthesia and Uncommon Diseases*. 6th ed. Philadelphia, PA: Elsevier 2012
21. Shenkman Z, Rockoff MA, Eldredge EA, Korf BR, Black PM, Soriano SG. Anaesthetic management of children with tuberous sclerosis. *Paediatr Anaesth* 2002;12:700–704

22. Hines RL, Marschall KE. *Stoelting's Anesthesia and Co-Existing Disease*. 5th ed. Philadelphia, PA: Churchill Livingstone 2008
23. Tuberous Sclerosis Alliance (Diagnosis, screening and clinical care of individuals with tuberous sclerosis complex. Tuberous Sclerosis Alliance. <https://www.tscalliance.org/healthcare-professionals/diagnosis/> (Accessed on 15. February 2022)
24. Krueger DA, Northrup H; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. *Pediatr Neurol* 2013;49: 255–265
25. Perks A, Cheema S, Mohanraj R. Anaesthesia and epilepsy. *Br J Anaesth* 2012;108:562–571
26. Septer S, Thompson ES, Willemsen-Dunlap A. Anesthesia concerns for children with tuberous sclerosis. *J Am Assoc Nurse Anesth* 2006;74:219–225
27. Diaz JH. Perioperative management of children with congenital phakomatoses. *Paediatr Anaesth* 2000;10:121–128
28. Kofke WA. Anesthetic management of the patient with epilepsy or prior seizures. *Curr Opin Anaesthesiol* 2010;23:391–399
29. Maranhão MV, Gomes EA, de Carvalho PE. Epilepsy and anesthesia. *Rev Bras Anestesiol* 2011;61:124–136, 232–241, 242–254
30. Artru AA, Lettich E, Colley PS, Ojemann GA. Nitrous oxide: suppression of focal epileptiform activity during inhalation, and spreading of seizure activity following withdrawal. *J Neurosurg Anesthesiol* 1990;2:189–193
31. Holzki J, Kretz FJ. Changing aspects of sevoflurane in paediatric anaesthesia: 1975–99. *Paediatr Anaesth* 1999;9:283–286
32. Tortella F. Endogenous opioid peptides and epilepsy: quieting the seizing brain? *Trends Pharmacol Sci* 1988;9:366–372
33. Saboory E, Derchansky M, Ismaili M, et al. Mechanisms of morphine enhancement of spontaneous seizure activity. *Anesth Analg* 2007;105:1729–1735
34. Hernández-Hernández MÁ, Iglesias-Posadilla D, Ruiz-Ruiz A, Gómez-Marcos V, Fernández-Torre JL. Matriz de densidad espectral de color del BIS bilateral en estado epiléptico [Colour density spectral array of bilateral bispectral index in status epilepticus]. *An Pediatr (Barc)* 2016;85:44–47
35. Manji RA, Grocott HP, Leake J, Ariano RE, Manji JS, Menkis AH, et al. Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors. *Can J Anaesth* 2012;59:6–13
36. Çetin C, Büyükkurt S, Demir C, Evrücke C. Renal angiomyolipoma during pregnancy: Case report and literature review. *Turk J Obstet Gynecol* 2015;12:118–121
37. Miller AD, Ball AM, Bookstaver PB, Dornblaser EK, Bennett CL. Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations. *Pharmacotherapy* 2011;31:408–423
38. Tuberous Sclerosis Alliance (Diagnosis, screening and clinical care of individuals with tuberous sclerosis complex. Tuberous Sclerosis Alliance. <https://www.tscalliance.org/healthcare-professionals/diagnosis/> (Accessed on 15th February 2022)
39. Leung AK, Robson WL. Tuberous sclerosis complex: a review. *J Pediatr Health Care* 2007;21:108–114
40. Schwartz RA, Fernández G, Kotulska K, Jóźwiak S. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. *J Am Acad Dermatol* 2007;57:189–202

41. Papaioannou EG, Staikou CV, Lambadarioui A, Karavokyros IG, Tsinari K. Anesthetic management of a patient with tuberous sclerosis presenting for renal transplantation. *J Anesth* 2003;17:193–195
42. Simmons JL, Hussain SA, Riley P, Wallace DM. Management of renal angiomyolipoma in patients with tuberous sclerosis complex. *Oncol Rep* 2003;10:237–241
43. Pacione D et al. Coagulation abnormalities in children undergoing epilepsy Surgery. *J Neurosurg Pediatr* 2011;7:654–659. DOI: 10.3171/2011.3.PEDS10559
44. Kuwabara N, Kuwahara T, Takahashi K, Goto H. Acute Pulmonary Embolism Resulting from Cardiac Tumors Associated with Tuberous Sclerosis. *Pediatr Cardiol* 2001;22:357–358
45. Fujimoto A et al. Magnetoencephalography using total intravenous anesthesia in pediatric patients with intractable epilepsy: Lesional vs nonlesional epilepsy. *Brain Dev* 2009;31:34–41
46. Al-Quteimat O, Laila A. Valproate Interaction With Carbapenems: Review and Recommendations. *Hosp Pharm* 2020;55:181–187
47. Davies M, Saxena A, Kingswood JC. Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide. *Orphanet J Rare Dis* 2017;15:35
48. Craig RG, Hunter JM. Recent developments in the perioperative management of adult patients with chronic kidney disease. *Br J Anaesth* 2008;101:296–310
49. Causse-Mariscal A, Palot M, Visseaux H, Daigremont-Botmans C, Malinovsky JM. Labor analgesia and cesarean section in women affected by tuberous sclerosis: report of two cases. *Int J Obstet Anesth* 2007;16:277–280
50. Bowditch J, Russell R, McCready S. General anaesthesia for caesarean section in a woman with tuberous sclerosis. *Int J Obstet Anesth* 2017;31:110–111.

Date last modified: **February 2022**

This recommendation was prepared by:

Authors

Louise Carter, Anaesthesiologist, Great Ormond Street Hospital, London, United Kingdom

Ioannis Ioannou, Paediatric Anaesthetist, Great Ormond Street Hospital, London, United Kingdom

Disclosure The authors have no financial or other competing interest to disclose. This recommendation was unfunded.

This recommendation was reviewed by:

Reviewers

Claudia Cuesta-González-Tascón, Pediatric Anaesthesia and Intensive Care; Hospital Infantil La Paz, Madrid, Spain

Franz Josef Kretz, Anaesthesiologist, Stuttgart, Germany

Matthias Sauter, Internal Medicine Specialist, Nephrologist, Infectiologist, Emergency Physician, Department of Hygiene and Infectiology, Klinikverbund Kempten-Oberallgäu, Germany
Matthias.Sauter@klinikum-kempten.de

Disclosure The reviewers have no financial or other competing interest to disclose.

Herausgeber



DGAI
Deutsche Gesellschaft
für Anästhesiologie und
Intensivmedizin e.V.
Präsident: Prof. Dr.
F. Wappler, Köln



BDA
Berufsverband Deutscher
Anästhesisten e.V.
Präsident: Prof. Dr.
G. Geldner, Ludwigsburg



DAAF
Deutsche Akademie
für Anästhesiologische
Fortbildung e.V.
Präsident: Prof. Dr.
H. Bürkle, Freiburg

Schriftleitung

Präsident/in der Herausgeberverbände
Gesamtschriftleiter/Editor-in-Chief:
Prof. Dr. Dr. Kai Zacharowski, Frankfurt
Stellvertretender Gesamtschriftleiter/
Deputy Editor:
Prof. Dr. T. Volk, Homburg/Saar
CME-Schriftleiter/CME-Editor:
Prof. Dr. W. Zink, Ludwigshafen

Redaktionskomitee/Editorial Board

Prof. Dr. G. Beck, Wiesbaden
Prof. Dr. A. Brinkmann, Heidenheim
Prof. Dr. H. Bürkle, Freiburg
Prof. Dr. B. Ellger, Dortmund
Prof. Dr. K. Engelhard, Mainz
Prof. Dr. M. Fischer, Göppingen
Prof. Dr. U. X. Kaisers, Ulm
Prof. Dr. T. Loop, Freiburg
Prof. Dr. W. Meißner, Jena
Prof. Dr. C. Nau, Lübeck
RAin A. Pfundstein, Nürnberg
Dr. M. Rähler, Mainz
Prof. Dr. A. Schleppers, Nürnberg
Prof. Dr. M. Thiel, Mannheim
Prof. Dr. F. Wappler, Köln
Prof. Dr. M. Weigand, Heidelberg

Redaktion/Editorial Staff

Carolin Sofia Kopp B.A.
Korrespondenzadresse:
Neuwieder Straße 9 | 90411 Nürnberg |
Deutschland | Tel.: 0911 9337812
E-Mail: anaesth.intensivmed@dgai-ev.de

Verlag & Druckerei

Aktiv Druck & Verlag GmbH
An der Lohwiese 36 |
97500 Ebelsbach | Deutschland
www.aktiv-druck.de



Geschäftsführung

Wolfgang Schröder | Jan Schröder |
Nadja Schwarz
Tel.: 09522 943560 | Fax: 09522 943567
E-Mail: info@aktiv-druck.de

Anzeigen | Vertrieb

Pia Müller | Robert Kux
Tel.: 09522 943570 | Fax: 09522 943577
E-Mail: anzeigen@aktiv-druck.de

Verlagsrepräsentanz

Jürgen Distler
Neuwieder Straße 9 | 90411 Nürnberg
Tel.: 0171 9432534
E-Mail: jdistler@bda-ev.de

Herstellung | Gestaltung

Pia Müller | Robert Kux |
Stefanie Triebert
Tel.: 09522 943570 | Fax: 09522 943577
E-Mail: ai@aktiv-druck.de

Titelbild

Gestaltung: Klaus Steigner
Paumgartnerstraße 28 | 90429 Nürnberg
E-Mail: mazyblue@klaus-steigner.de
www.klaus-steigner.de

Erscheinungsweise 2022

Der 63. Jahrgang erscheint jeweils zum
Monatsanfang, Heft 7/8 als Doppelausgabe.

Bezugspreise (inkl. Versandkosten):

• Einzelhefte	30,- €
• Jahresabonnement:	
Europa (ohne Schweiz)	258,- €
(inkl. 7 % MwSt.)	
Schweiz	266,- €
Rest der Welt	241,- €

Mitarbeiter aus Pflege, Labor, Studenten und Auszubildende (bei Vorlage eines entsprechenden Nachweises)

Europa (ohne Schweiz)	94,- €
(inkl. 7 % MwSt.)	
Schweiz	90,- €
Rest der Welt	94,- €

**Für Mitglieder der DGAI und/oder
des BDA ist der Bezug der Zeitschrift
im Mitgliedsbeitrag enthalten.**

Allgemeine Geschäfts- und Liefer- bedingungen

Die allgemeinen Geschäfts- und Liefer-
bedingungen entnehmen Sie bitte dem
Impressum auf www.ai-online.info

Indexed in **Current Contents®/Clinical
Medicine, EMBASE/Excerpta Medica;
Medical Documentation Service;
Research Alert; Sci Search; SUBIS
Current Awareness in Biomedicine;
VINITI: Russian Academy of Science.**

Nachdruck | Urheberrecht

Die veröffentlichten Beiträge sind urhe-
berrechtlich geschützt. Jegliche Art von
Vervielfältigungen – sei es auf mechani-
schem, digitalem oder sonst möglichem
Wege – bleibt vorbehalten. Die Aktiv
Druck & Verlags GmbH ist allein auto-
risiert, Rechte zu vergeben und Sonder-
drucke für gewerbliche Zwecke, gleich
in welcher Sprache, herzustellen. An-
fragen hierzu sind nur an den Verlag zu
richten. Jede im Bereich eines gewerbli-
chen Unternehmens zulässig hergestellte
oder benutzte Kopie dient gewerblichen
Zwecken gem. § 54 (2) UrhG. Die Wie-
dergabe von Gebrauchsnamen, Handels-
namen, Warenbezeichnungen usw. in
dieser Zeitschrift berechtigt auch ohne
besondere Kennzeichnung nicht zu der
Annahme, dass solche Namen im Sinne
der Warenzeichen- und Markenschutz-
Gesetzgebung als frei zu betrachten wä-
ren und daher von jedermann benutzt
werden dürften.

Wichtiger Hinweis

Für Angaben über Dosierungsanwei-
sungen und Applikationsformen kann
vom Verlag und den Herausgebern keine
Gewähr übernommen werden. Derartige
Angaben müssen vom jeweiligen An-
wender im Einzelfall anhand anderer
Literaturstellen auf ihre Richtigkeit über-
prüft werden. Gleiches gilt für berufs-
und verbandspolitische Stellungnahmen
und Empfehlungen.

Allein aus Gründen der besseren Les-
barkeit wird auf die gleichzeitige Ver-
wendung männlicher, weiblicher und
weiterer Sprachformen verzichtet. Sämt-
liche Personenbezeichnungen gelten für
alle Geschlechterformen. Dies impliziert
keinesfalls eine Benachteiligung der je-
weils anderen Geschlechter, sondern ist
als geschlechtsneutral zu verstehen.

CONTACT US

Please do not hesitate to contact us. We will be glad to answer and provide further information to you at any time.

.....
Name

.....
First Name

.....
Department / Hospital

.....
Place

.....
Telephone

.....
E-Mail

.....
Date / Signature

Please contact me for further information

I would like to participate in the project

ADDRESS

German Society of Anaesthesiology and
Intensive Care Medicine
Ursula Homberg
Neuwieder Straße 9 | 90411 Nuremberg | Germany
Tel.: +49-911-9337828
Email: uhomberg@orphananesthesia.eu